Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:CPHD
Previous Symbol
CUSIP15670R10
Phone+1-408-5414191
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees1,700
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Cepheid (NASDAQ:CPHD) Frequently Asked Questions
What is Cepheid's stock symbol?
Cepheid trades on the NASDAQ under the ticker symbol "CPHD."
How were Cepheid's earnings last quarter?
Cepheid (NASDAQ:CPHD) issued its quarterly earnings data on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. Cepheid's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. View Cepheid's Earnings History.
Has Cepheid been receiving favorable news coverage?
News headlines about CPHD stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cepheid earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the scientific and technical instruments company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Cepheid?
Shares of CPHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cepheid's stock price today?
One share of CPHD stock can currently be purchased for approximately $52.95.
What is Cepheid's official website?
How can I contact Cepheid?
Cepheid's mailing address is 904 E Caribbean Dr, SUNNYVALE, CA 94089-1189, United States. The scientific and technical instruments company can be reached via phone at +1-408-5414191.
MarketBeat Community Rating for Cepheid (NASDAQ CPHD)
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe CPHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
